Literature DB >> 23456099

One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Yasuhiro Ohkuma1, Takaaki Hayashi, Tsutomu Sakai, Akira Watanabe, Hiroshi Tsuneoka.   

Abstract

PURPOSE: To evaluate the efficacy of reduced-fluence photodynamic therapy (RFPDT) for central serous chorioretinopathy (CSC).
METHODS: This retrospective medical record review of consecutive CSC patients treated with RFPDT (full-dose verteporfin and laser fluence of 25 J/cm(2)) examined 22 eyes of 21 patients (20 males and one female). All patients were followed-up for 1 year. Best-corrected visual acuity (BCVA), complete resolution of subretinal fluid (CR of SRF), central retinal thickness (CRT), the outer nuclear layer (ONL) thickness, and the photoreceptor inner and outer segments (IS/OS) line determined by optical coherence tomography imaging were evaluated at baseline, 1, 3, 6, 9, and 12 months after initial RFPDT.
RESULTS: A single RFPDT session was performed in all cases during a 12-month period. CR of SRF was identified in all patients. BCVA significantly improved between 3 and 12 months (P < 0.05). The CRT significantly decreased between 1 and 12 months. A significantly thicker ONL was observed at 1 month, and 17 eyes (77.2 %) showed recovery of the continuous foveal IS/OS line. ONL thickness was correlated with BCVA at 12 months (P < 0.01). Stepwise analysis indicated that pre-treatment BCVA (P < 0.01) and ONL thickness (P < 0.01) were significant predictive factors for BCVA at 12 months. Neither ocular nor systemic adverse effects were observed during the follow-up period.
CONCLUSION: RFPDT appears to be an effective treatment method for CSC. ONL thickness is an important visual predictive factor of RFPDT for CSC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456099     DOI: 10.1007/s00417-013-2289-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  37 in total

1.  The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy.

Authors:  Felice Cardillo Piccolino; Roberta Rigault de la Longrais; Giambattista Ravera; Chiara M Eandi; Luca Ventre; Ali' Abdollahi; Marilisa Manea
Journal:  Am J Ophthalmol       Date:  2005-01       Impact factor: 5.258

2.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

3.  Ultrahigh-resolution optical coherence tomography in patients with decreased visual acuity after retinal detachment repair.

Authors:  Lisa S Schocket; Andre J Witkin; James G Fujimoto; Tony H Ko; Joel S Schuman; Adam H Rogers; Caroline Baumal; Elias Reichel; Jay S Duker
Journal:  Ophthalmology       Date:  2006-04       Impact factor: 12.079

4.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

5.  Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; David T L Liu; Dennis S C Lam
Journal:  Ophthalmology       Date:  2008-06-05       Impact factor: 12.079

6.  Indocyanine green angiographic findings in central serous chorioretinopathy.

Authors:  C Prünte
Journal:  Int Ophthalmol       Date:  1995       Impact factor: 2.031

7.  Digital indocyanine green videoangiography of central serous chorioretinopathy.

Authors:  D R Guyer; L A Yannuzzi; J S Slakter; J A Sorenson; A Ho; D Orlock
Journal:  Arch Ophthalmol       Date:  1994-08

8.  Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.

Authors:  Michele Reibaldi; Nicola Cardascia; Antonio Longo; Claudio Furino; Teresio Avitabile; Salvatore Faro; Marisa Sanfilippo; Andrea Russo; Maurizio Giacinto Uva; Ferdinando Munno; Vincenzo Cannemi; Marco Zagari; Francesco Boscia
Journal:  Am J Ophthalmol       Date:  2009-11-06       Impact factor: 5.258

9.  Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; Emily W H Tang; David T L Liu; Dennis S C Lam
Journal:  Retina       Date:  2008-01       Impact factor: 4.256

10.  Cystoid macular degeneration in chronic central serous chorioretinopathy.

Authors:  Tomohiro Iida; Lawrence A Yannuzzi; Richard F Spaide; Natalie Borodoker; Cynthia A Carvalho; Silvana Negrao
Journal:  Retina       Date:  2003-02       Impact factor: 4.256

View more
  9 in total

1.  Threshold thickness of foveal outer nuclear layer associated with outcomes of photodynamic therapy in central serous chorioretinopathy.

Authors:  Qing Chang; Gezhi Xu; Jia Yu; Xiaofeng Ye; Lei Li; Chunhui Jiang
Journal:  Eye (Lond)       Date:  2021-09-03       Impact factor: 4.456

2.  Early anatomical changes and association with photodynamic therapy induced acute exudative maculopathy in patients with macular diseases.

Authors:  Satoshi Honda; Takeya Kohno; Manabu Yamamoto; Kumiko Hirayama; Akika Kyo; Michiko Hirabayashi; Shigeru Honda
Journal:  Sci Rep       Date:  2022-06-01       Impact factor: 4.996

3.  Directional Optical Coherence Tomography Reveals Reliable Outer Nuclear Layer Measurements.

Authors:  Kevin K Tong; Brandon J Lujan; Yixiu Zhou; Meng C Lin
Journal:  Optom Vis Sci       Date:  2016-07       Impact factor: 1.973

4.  Efficacy of reduced-fluence photodynamic therapy for serous retinal pigment epithelial detachment with choroidal hyperpermeability.

Authors:  Asako Shibata; Yasuhiro Ohkuma; Takaaki Hayashi; Hiroshi Tsuneoka
Journal:  Clin Ophthalmol       Date:  2013-10-30

5.  Inter- and Intra-individual Variations in Foveal Outer Nuclear Layer Thickness and Their Associations with Clinical Characteristics in a Healthy Chinese Population.

Authors:  Jia Yu; Lei Li; Chunhui Jiang; Qing Chang; Qi Zhao
Journal:  J Ophthalmol       Date:  2020-05-24       Impact factor: 1.909

6.  Outer Nuclear Layer as the Main Predictor to Anatomic Response to Half Dose Photodynamic Therapy in Chronic Central Serous Retinopathy.

Authors:  Keissy Sousa; Ana Rita Viana; Joana Pires; Carla Ferreira; Lara Queirós; Manuel Falcão
Journal:  J Ophthalmol       Date:  2019-10-13       Impact factor: 1.909

Review 7.  Advances in the treatment of central serous chorioretinopathy.

Authors:  Marwan A Abouammoh
Journal:  Saudi J Ophthalmol       Date:  2015-01-24

8.  Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.

Authors:  Thomas J van Rijssen; Danial Mohabati; Greet Dijkman; Thomas Theelen; Eiko K de Jong; Elon H C van Dijk; Camiel J F Boon
Journal:  PLoS One       Date:  2018-08-24       Impact factor: 3.240

9.  532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy.

Authors:  Keissy Sousa; Gil Calvão-Santos; Marina João; Nuno Gomes; Manuel Falcão
Journal:  Clin Ophthalmol       Date:  2020-02-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.